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1. Introduction
   Toxoplasmosis is the most common parasitic disease in the 
world. The most common form of the disease in humans is 
asymptomatic but it may be fatal in immunocompromised patients 
and congenitally infected fetuses and newborns[1]. Recent data 
showed that latent toxoplasmosis is not only hazardous for 
human, but also may play various roles in the etiology of several 
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Objective: To investigate the possible association between Toxoplasma gondii (T. gondii) 
infection and breast cancer by examining the seropositivity and serointensity rate of anti-T. 
gondii antibodies in breast cancer patients and healthy volunteers. 
Methods: This study was carried out on 66 women with breast cancer which consists of 29 
newly diagnosed patients (Group 1) and 37 cases undergoing treatment and regular checkups 
(Group 2). Also, 60 healthy women (Group 3) with no history of cancer confirmed by clinical 
examination and imaging participated in this study. The participants were tested for T. gondii 
immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies by enzyme-linked 
immunoassays. 
Results: The mean age of Groups 1, 2 and 3 were 43.3±6.8, 41.8±5.5 and 42.3±4.9, 
respectively (P=0.72). Overall, 104 (82.5%) and 8 (6.3%) out of 126 women were positive for 
anti-T. gondii IgG and IgM antibodies, respectively. Higher seropositivity rate of anti-T. gondii 
antibodies (IgG) was seen in breast cancer patients (86.4%) compared with control group 
(78.3%) (P=0.24). IgG antibodies were detected in 89.2% of cancer patients under treatment, 
82.7% of newly diagnosed patients (P=0.18). IgM antibodies were found in 3 (10.3%), 2 (5.4%) 
and 3 (5%) in Groups 1, 2 and 3. No significant difference was found between the mean titers 
of T. gondii IgG antibody among these groups (P=0.87). 
Conclusions: This study did not find any significant association between toxoplasmosis and 
breast cancer besides higher rates of seropositivity and serointensity in patients compared with 
healthy volunteers.  
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gondii antibodies (IgG and IgM) in three 
study arms; and showed higher rates of 
seropositivity and serointensity in breast 
cancer patients than in healthy controls, 
and reported no association between 
human T. gondii infection and breast 
cancer. Such a study would provide insight 
into the management of breast cancer 
patients.
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diseases such as mental disorders[1-3]. Moreover, reactivation of the 
parasite or disseminated acute infection may occur in patients with 
acquired immunodeficiency virus, in organ transplant recipients, 
and in patients with malignancy such as leukemia, lymphoma, and 
solid tumors[4-10]. Generally, these patients have been treated with 
corticosteroids and cytotoxic agents which reduced immune system 
response and lead to reactivation of the dormant parasite[11]. On the 
other hand, Toxoplasma gondii (T. gondii) has been shown to be able 
to activate cellular immunity in the animals[12]. Recently, several 
studies have demonstrated that parasitic or bacterial infections 
possess antitumor activities against certain types of cancers[13,14]. 
For instance, a study showed that injection of T. gondii and 
Toxocara canis antigens is associated with a significant reduction 
in the tumor size in comparison with the control group[13]. While 
the results obtained from the other studies strongly indicated that 
T. gondii potentially increases the risk of brain cancer in humans 
or in adult patients with brain cancer aged 55 years or older. Also, 
the regional mortality rates have positively correlated with the 
local seroprevalence of T. gondii, which suggested that T. gondii 
should be investigated further as a possible oncogenic pathogen to 
humans[15,16]. 
   Breast cancer is the most common cancer in women throughout 
the world. In 2008, 22.9% of all new cancers were related to breast 
cancer. In spite of good prognosis of this malignancy, it was also 
the most common cause of death related to cancer. Based on the 
annual report of Health Deputy of Ministry of Health and Medical 
Education in Iran, breast cancer in Mazandaran Province is the most 
common cancer of women[17]. On the other hand, T. gondii infection 
has been reported very high in this region and most women get 
infection before 25 years old[18,19]. The role of T. gondii to cause 
severe symptoms in immunocompromised cases has been studied 
widely, but toxoplasmosis in immunocompromised patients with 
cancer has not been considered well. The current study aimed to 
investigate the association between T. gondii infection and breast 
cancer by testing the seropositivity rate of anti-T. gondii antibodies 
[immunoglobulin G (IgG) and immunoglobulin M (IgM)] in breast 
cancer patients and healthy volunteers.
2. Methods and materials
2.1. Population study 
   This cross sectional study was performed on women with breast 
cancer that are between 20 to 50 years old, referring to Ayatolah 
Rohani Hospital and Shaheed Rajaee Hospital from January 21st, 
2012 to January 21st, 2013. The participants of this study were 
divided into three groups. Group 1 consists of 29 patients with breast 
cancer recently diagnosed. Group 2 consists of 37 patients with 
breast cancer undergoing radiotherapy or chemotherapy and under 
regular checkups. Group 3 consists of 60 healthy women with no 
history of cancer confirmed by clinical examination and imaging. 
In addition to demographic data, the outcome of disease, stage of 
cancer, period of chemotherapy were recorded.  
2.2. Sample collection
   A total of 2 mL blood samples were taken from each participant. 
The collected blood samples were centrifuged at 2 000 r/min for 
5 min to gain serum. The serum was separated and then stored at 
-20°oC until required. After sample collection, the frozen sera were 
thawed at room temperature and tested for existence of anti-T. gondii 
antibodies, IgG and IgM, using a commercial ELISA kits (Genesis 
Toxoplasma IgG, and Genesis Toxoplasma IgM, UK). Based on 
the manufacturer’s instruction, the optical density of IgG and IgM 
antibody titers were read at 450 nm using automatic ELISA reader. 
The sera IgG titer <8 IU/mL was considered negative for anti-T. 
gondii IgG antibodies and >8 IU/mL positive. Additionally, the sera 
that were IgG positive were further divided into two groups: low 
positive sera (IgG titer between 8-50 IU/mL) and high positive sera 
(IgG titer >50 IU/mL).
2.3. Statistical analysis and ethic consideration
   The data were processed and analyzed by SPSS version 18.0. One-
way ANOVA, Fisher’s exact test and Chi-square tests were used to 
analyze the data at 95% confidence level and a P value less than 0.05 
was considered statistically significant. This study was approved by 
the Ethic Committee of the Research Council of Babol University 
of Medical Sciences, Babol, Iran. The purpose of the study was 
explained in details to all the participants, and all the contributors 
consent to share. 
3. Results
   In total, 126 women participated in this study, including 29, 37 
and 60 cases in Groups 1, 2 and 3, respectively. The mean age and 
standard deviation of women in Groups 1, 2 and 3 were 43.3±6.8, 
41.8±5.5 and 42.3±4.9, respectively. There were no statistically 
significant differences between the mean age of patients and healthy 
cases (P=0.72, F=0.328, df=123). All participants lived in urban 
areas. Overall, 104 (82.5%) and 8 (6.3%) women were positive for 
anti-T. gondii IgG and IgM antibodies, respectively. Anti-T. gondii 
IgG and IgM antibodies detected in cancer patients and controls were 
presented in Table 1. The results showed that higher seropositivity 
rate of anti-T. gondii antibodies (IgG) was 86.4% in breast cancer 
patients compared with the controls (78.3%). The difference of 
IgM seropositivity rate among studied groups was not statistically 
significant (P=0.24). 
   Furthermore, prevalence rate of anti-T. gondii antibodies (IgG) in 
patients under treatment and regular checkups (89.2%) was higher 
than newly diagnosed patients (82.7%), but this difference was not 
statistically significant (P=0.18). 
   Five out of 66 (7.6%) breast cancer patients and three out of 
60 (5.0%) healthy women were positive for anti-T. gondii IgM 
antibodies (Table 1). Among patients group, three out of 29 (10.3%) 
newly diagnosed patients and two out of 37 (5.4%) under treatment 
cases were positive for IgM. These cases were positive for IgG 
antibodies, simultaneously. No statistically significant difference 
of IgM seropositivity rate was found among the studied groups 
(P=0.60). Moreover, any clinical manifestations of toxoplasmosis 
were not observed in all studied groups. 
  Table 1
The distribution of seroprevalence of T. gondii IgG and IgM antibodies in the 
cancer patients and control groups. 
Antibodies Patients group
(n=66)     
Control group
(n=60) 
P value
IgG(+)   57 (86.4%)        47 (78.3%) 0.24
IgG(-)     9 (13.6%)         13 (21.7%)
IgM(+)   5 (7.6%)     3 (5.0%) 0.60
IgM(-)   61 (92.4%)     57 (95.0%)
P value is obtained by Chi-square and Fisher’s exact test.
 
   Mean titers of anti-T. gondii IgG antibody in Groups 1, 2 and 3 
were 27.6 IU/mL, 28.2 IU/mL and 25.4 IU/mL, respectively. No 
statistically significant difference of mean titers was seen among 
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the studied populations (F=0.139, df=125, P=0.87). Furthermore, 
serointensity rate of anti-T. gondii IgG antibody (>50 IU/mL) was 
higher in cancer patients 15.8% (9 out of 57) compared with healthy 
women 6.4% (3 out of 47) (P=0.11) (Table 2). Relationship between 
serointensity rate of anti-T. gondii IgG antibody and age were also 
shown in Table 2. 
Table 2 
Relationship between serointensity rates of anti-T. gondii antibodies (IgG) 
and breast cancer and age.
Variables Number Serointensity rate P value
High n (%) Low n (%)
Groups Patients 57     9 (15.8) 48 (84.2) 0.11
Control 47   3 (6.4) 44 (93.6)
Age groups >43 49   3 (6.1) 46 (93.9) 0.09
<43 55     9 (16.4) 49 (83.6)
P value is obtained by Chi-square and Fisher’s exact test.
   Furthermore, cancer metastasized to liver and bone in three 
patients. All these three patients were positive for anti- T. gondii IgG 
antibody. The IgG titers ranged from 12 to 16.6 IU/mL indicating 
that the infection had occurred long time ago. 
4. Discussion
   Toxoplasma infection in association with different malignancy has 
been described by several studies[7,10,20,21]. An early study showed 
that 93.7% women with genital tract and breast cancer were positive 
for anti-T. gondii antibodies and 20.46% of them had antibody titers 
at 1:400 or higher[22]. A recent study reported higher seroprevalence 
rate of toxoplasmosis in breast cancer patients following leukemia 
and lymphoma[7]. The current work is the first preliminary study in 
Iran that investigated the seroprevalence rate of T. gondii in breast 
cancer patients in order to find out any possible association between 
this infection and breast cancer. The findings demonstrated that the 
positivity rate for T. gondii IgG antibodies was higher in patients 
(86.4%) compared with the healthy women (78.3%). It also showed 
that seroprevalence rate of toxoplasmosis was higher in patients who 
were under treatment and regular checkups than newly diagnosed 
patients. But statistically significant differences were not observed. 
These findings suggest that not only Toxoplasma infection but 
also treatment did not have significant relationship between breast 
cancer and seropositivity rates of toxoplasmosis. With excepting 
the kind of cancer, these findings are in agreement with other 
studies which reported that seroprevalence rate of toxoplasmosis 
in cancer patients was higher than that in healthy individuals[11,23]. 
However, these results are in contrast with other reports which 
found significant relationship between Toxoplasma infection and 
cancer. This significant association was particularly seen between 
T. gondii infection and brain cancer[10,15,16,24,25].
   On the other hand, the positivity rates of anti-T. gondii IgG in 
breast cancer patients (86.4%) and healthy volunteers (78.3%) were 
much higher than that reported by other researchers[7,10,11]. These 
findings could be due to many reasons such as the geographical 
variation, customs and habits, difference in genetic susceptibility 
and the possible risk factors contributing to the acquisition of 
Toxoplasma infection[23]. Indeed, several seroepidemiological 
studies have reported that there is higher prevalence rate of 
Toxoplasma infection in Northern Iran where the current study 
was performed[19,26]. In addition, age is an important associated 
factor in the epidemiology of Toxoplasma infection which made 
limitation in the current work. Many studies demonstrated that the 
seroprevalence rate of toxoplasmosis increases with age and the 
peak level was seen in cases older than 50 years[26,27]. Also, the 
incidence of breast cancer increases rapidly with age during the 
reproductive years and then increases at a slower rate after about 
age of 50 years[28]. However, this study showed that breast cancer 
is more prevalent (69.7%) in women who are more than 40 years 
of age. According to T. gondii IgM antibodies results, there was 
not statistically significant difference between the breast cancer 
patients and healthy women, which was consistent with the other 
reported data[10,23]. 
   In addition, the high serointensity rate of anti-T. gondii IgG 
antibody was not statistically higher in cancer patients (15.8%) 
compared with healthy women (6.4%) (P<0.11). Although, 
Toxoplasma has been considered as an opportunistic infection, we 
did not find significant association between Toxoplasma infection 
and breast cancer. Age is a critical factor for both breast cancer and 
toxoplasmosis which are more prevalent in women aged over 40 
years. Indeed, Toxoplasma infection occurred in people at lower 
age in our region where the study preformed[26,27]. Therefore, we 
did not find any significant association between toxoplasmosis and 
breast cancer as the mean age of the studied population was 42.3 
years. Another possible reason is small sample size. 
   It was also not statistically higher in cases older than 43 years 
(16.4%) compared with individuals younger than 43 years (6.1%)
(P<0.09). This finding is in line with other study demonstrating 
that the seroprevalence rate of toxoplasmosis increase with age[26]. 
   In conclusion, the current study did not find any significant 
association between toxoplasmosis and breast cancer besides the 
higher rates of seropositivity and serointensity in patients compared 
with healthy volunteers. Furthermore, no clinical manifestations 
of toxoplasmosis were seen in the studied groups. This work also 
suggested that further studies should be performed to establish any 
association between T. gondii and breast cancer.
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Comments 
Background
   Toxoplasmosis, a global parasitic disease, is usually asymptomatic 
in healthy subjects, but is fatal in immunocompromised patients, 
including HIV patients, cancer patients, organ transplantation 
recipients, etc. This study examined the possible correlation 
between T. gondii infection and risk of breast cancer. 
Research frontiers
   This study detected seroprevalence and serointensity of anti-T. 
gondii antibodies IgG and IgM in recently diagnosed breast 
cancer patients, breast cancer patients undergoing radiotherapy or 
chemotherapy, and healthy controls. The results showed higher 
rates of seropositivity and serointensity in breast cancer patients 
than in healthy controls, and reported no association between 
human T. gondii infection and breast cancer. 
Related reports
   The seroprevalence and serointensity of anti-T. gondii antibodies 
IgG and IgM have been extensively investigated in cancer patients. 
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Applications
   Based on the results from this study, it is concluded that the 
seroprevalence and serointensity of anti-T. gondii antibodies IgG are 
higher in breast cancer patients than in healthy individuals.    
Peer review
   This cross-sectional study actually investigated and compared 
the seroprevalence and serointensity of anti-T. gondii antibodies 
(IgG and IgM) in three study groups, and showed higher rates of 
seropositivity and serointensity in breast cancer patients than in 
healthy controls, and reported no association between human T. 
gondii infection and breast cancer. Such a study would provide 
insight into the management of breast cancer patients.
References
[1]    Dalimi A, Abdoli A. Latent toxoplasmosis and human. Iran J Parasitol 
2012; 7: 1-17.
[2]    Emelia O, Amal RN, Ruzanna ZZ, Shahida H, Azzubair Z, Tan KS, et al. 
Seroprevalence of anti-Toxoplasma gondii IgG antibody in patients with 
schizophrenia. Trop Biomed 2012; 29: 151-159.
[3]    Alipour A, Shojaee S, Mohebali M, Tehranidoost M, Abdi Masoleh 
F, Keshavarz H. Toxoplasma infection in schizophrenia patients: a 
comparative study with control group. Iran J Parasitol 2011; 6: 31-37.
[4]    Black MW, Boothroyd JC. Lytic cycle of Toxoplasma gondii. Microbiol 
Mol Biol Rev 2000; 64: 607-623.
[5]    Derouin F, Pelloux H, ESCMID Study Group on Clinical Parasitology. 
Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 
2008; doi: 10.1111/j.1469-0691.2008.02091.x.
[6]    Alvarado-Esquivel C, Liesenfeld O, Torres-Castorena A, Estrada-
Martínez S, Urbina-Alvarez JD, Ramos-de la Rocha M, et al. 
Seroepidemiology of Toxoplasma gondii infection in patients with vision 
and hearing impairments, cancer, HIV, or undergoing hemodialysis in 
Durango, Mexico. J Parasitol 2010; 96: 505-508.
[7]    Nimir A, Othman A, Ee S, Musa Z, Majid IA, Kamarudin Z, et al. Latent 
toxoplasmosis in patients with different malignancy: a hospital based 
study. J Clin Med Res 2010; 2: 117-120.
[8]    Israelski DM, Remington JS. Toxoplasmosis in patients with cancer. 
Clin Infect Dis 1993; 17: S423-S435.
[9]    Ryan P, Hurley SF, Johnson AM, Salzberg M, Lee MW, North JB, et al. 
Tumours of the brain and presence of antibodies to Toxoplasma gondii. 
Int J Epidemiol 1993; 22: 412-419.
[10]  Yuan Z, Gao S, Liu Q, Xia X, Liu X, Liu B, et al. Toxoplasma gondii 
antibodies in cancer patients. Cancer lett 2007; 254: 71-74.
[11]  Khabaz MN, Elkhateeb L, Al-Alami J. Reactivation of latent Toxoplasma 
gondii in immunocompromised cancer patients. Comp Clin Pathol 2011; 
20: 183-186.
[12]  Bolhassani A, Zahedifard F. Therapeutic live vaccines as a potential 
anticancer strategy. Int J Cancer 2012; 131: 1733-1743. 
[13]  Darani HY, Shirzad H, Mansoori F, Zabardast N, Mahmoodzadeh M. 
Effects of Toxoplasma gondii and Toxocara canis antigens on WEHI-
164 fibrosarcoma growth in a mouse model. Korean J Parasitol 2009; 
47: 175-177. 
[14]  Kim JO, Jung SS, Kim SY, Kim TY, Shin DW, Lee JH, et al. Inhibition 
of Lewis lung carcinoma growth by Toxoplasma gondii through 
induction of Th1 immune responses and inhibition of angiogenesis. J 
Korean Med Sci 2007; 22: S38-S46.
[15]  Thomas F, Lafferty KD, Brodeur J, Elguero E, Gauthier-Clerc M, Missé 
D. Incidence of adult brain cancers is higher in countries where the 
protozoan parasite Toxoplasma gondii is common. Biol Lett 2011; doi: 
10.1098/rsbl.2011.0588.
[16]  Vittecoq M, Elguero E, Lafferty KD, Roche B, Brodeur J, Gauthier-
Clerc M, et al. Brain cancer mortality rates increase with Toxoplasma 
gondii seroprevalence in France. Infect Genet Evol 2012; 12: 496-498.
[17]  Islamic Republic of Iran, Ministry of Health and Medical Education, 
Office of Deputy Minister for Health Center for Disease Control, 
Cancer Office. Iranian Annual National Cancer Registration Report, 
2006-2007. Tehran: Iranian Ministry of Health and Medical Education; 
2007. 
[18]  Bayani M, Mostafazadeh A, Oliaee F, Kalantari N. The Prevalence of 
Toxoplasma gondii in Hemodialysis Patients. Iran Red Crescent Med J 
2013; 15: e5225. 
[19]  Kalantari N, Ghaffari S, Bayani M, Agapour R, Zeinalzadeh M, 
Gavipanjeh F, et al. [Serological study of toxoplasmosis in pregnant 
women in Babol, Northern Iran 2012-2013]. J Ilam Univ Med Sci 2014; 
22: 102-108. Persian.
[20]  Fallahi Sh, Kazemi B, Seyyed tabaei SJ, Bandehpour M, Lasjerdi Z, 
Taghipour N, et al. Comparison of the RE and B1 gene for detection of 
Toxoplasma gondii infection in children with cancer. Parasitol Int 2014; 
63: 37-41.
[21]  Alibek K, Kakpenova A, Baiken Y. Role of infectious agents in the 
carcinogenesis of brain and head and neck cancers. Infect Agent Cancer 
2013; 8(1): 7. 
[22]  Sanchis-Belenguer R, Cuadrado-Méndez L, Ortiz Muńoz AB. [Possible 
interactions between Toxoplasma gondii infection and the presence of 
carcinomas of female genitalia and the breast]. Rev Esp Oncol 1984; 
31: 247-255. Spanish.
[23]  Ghasemian M, Maraghi Sh, Saki J, Pedram M. Determination of 
antibodies (IgG, IgM) against Toxoplasma gondii in patients with 
cancer. Iran J Parasitol 2007; 2: 1-6.
[24]  Thirugnanam S, Rout N, Gnanasekar M. Possible role of Toxoplasma 
gondii in brain cancer through modulation of host microRNAs. Infect 
Agent Cancer 2013; 8: 8. 
[25]  Yazar S, Yaman O, Eser B, AltuntasşF, Kurnaz F, ŞSahin I. Investigation 
of anti-Toxoplasma gondii antibodies in patients with neoplasia. J Med 
Microbiol 2004; 53: 1183-1186.
[26]  Daryani A, Sarvi S, Aarabi M, Mizani A, Ahmadpour E, Shokri A, et al. 
Seroprevalence of Toxoplasma gondii in the Iranian general population: 
a systematic review and meta-analysis. Acta Trop 2014; 137: 185-194.
[27]  Lim H, Lee SE, Jung BK, Kim MK, Lee MY, Nam HW, et al. Serologic 
survey of toxoplasmosis in Seoul and Jeju-do, and a brief review of its 
seroprevalence in Korea. Korean J Parasitol 2012; 50: 287-293.
[28]  Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet 
Oncol 2001; 2: 133-140.
